🌟Vedolizumab & Ustekinumab: Safe for IBD Moms? 🌟

📊 Study: EPI-MERES registry (2014–2021).
🧪 Results:
✅ No extra risks vs. anti-TNFs.
⚠️ Ustekinumab: Slightly higher risk of small-for-gestational-age births.

💡 Conclusion: Reassuring safety, but more research needed!

🔬🚀 #CrohnsDisease News‼️

🔗📘 tinyurl.com/ydwentvd

✅The REPREVIO trial

Early vedolizumab after ileocolonic surgery drastically cuts severe #Crohns recurrence (23.3% vs. 62.2%) and boosts the chance of lower Rutgeerts scores (77.8%)! 💪

✨ Fewer flares, better outcomes‼️

💡 AI-assisted peer review is a promising tool, but adoption is fragmented & policies unclear.

🛟Safeguards against bias & breaches are critical.

💡With careful use, AI can enhance productivity while maintaining integrity.

‼️Continuous monitoring is essential! 🔍

📰 Key findings from top 100 medical journals:
🔹 78% provide AI peer review guidance.
❌ 59% prohibit AI use, mainly over confidentiality concerns (96%).
✅ 32% allow limited use with conditions like disclosure.
🌐 Global journals are more flexible than US/Europe-based ones.

🔥📚 Peer review is under pressure‼️

Can 🤖 AI be the solution?

📚🔗 tinyurl.com/44pt9m3f

A study dives into medical journals’ policies on AI-assisted peer review to uncover the trends. 🚀

🚀 First Virtual Reality in Endoscopy Training! 🎮🩺

A big 🙏 you to Boston Scientific, University Hospital Motol, 2nd Faculty of Medicine, Charles University, and 3NDO for their incredible support! 🙌👏

Pushing the boundaries of education and innovation in endoscopy! 🌍✨

💠Conclusion:

✅Resmetirom is a game-changer for MASH, but precise patient selection is 🔑. Let’s optimize outcomes! 💡

💠Results:
📊 Target population: MASH with fibrosis stages 2-3.
✅ Promise: First FDA-approved 💊 offering hope for noncirrhotic MASH.

💠Challenges:
🩺 Noninvasive tools to identify F2-F3 patients.
⛔ Excluding advanced fibrosis until more data is available.

🚨 New Expert Panel Recomm. Alert 🚨

🔗📗 tinyurl.com/3he6rybk

💡Expert panel shares practical tips on initiating & monitoring #Resmetirom for #MASH with moderate to advanced fibrosis.

@cugastrohep.bsky.social @amergastroassn.bsky.social @aga-cgh.bsky.social

🧪 Combination therapy: TNF antagonists + immunomodulators > monotherapy.
🕒 Early escalation: Advanced therapies > step-up after 5-ASA failure.

✅ Top therapies: Infliximab, vedolizumab, upadacitinib, ozanimod, etrasimod, ustekinumab, risankizumab, and guselkumab.
👩‍⚕️ Advanced-naïve patients: Prefer higher-efficacy meds (e.g., infliximab) for remission.
🚫 Avoid thiopurine/methotrexate monotherapy for induction.

🚨 New AGA Guideline 🚨

🔗📗 tinyurl.com/mwc4ve42

💡An updated for the pharmacological management of moderate-to-severe #ulcerativecolitis.

A patient-centered, evidence-based guide to empower practitioners! 💊

@ibddoctor.bsky.social @ibd-afzali.bsky.social @bottomlineibd.bsky.social